Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

2013; Elsevier BV; Volume: 121; Issue: 23 Linguagem: Inglês

10.1182/blood-2013-01-480228

ISSN

1528-0020

Autores

Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia‐Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan A. Burger, Tapan M. Kadia, Sara Dellasala, Michael Andreeff, Jorge E. Cortés, Hagop M. Kantarjian, Mark J. Levis,

Tópico(s)

Myeloproliferative Neoplasms: Diagnosis and Treatment

Resumo

Key Points Azacytidine and sorafenib are effective in patients with relapsed and refractory FLT3-mutated AML.

Referência(s)